Alzheimer’s disease (AD) is one of the most challenging conditions, affecting millions of people worldwide. It often begins with subtle memory lapses, progressing to severe cognitive impairment. However, in the early stages of Alzheimer’s, a new infusion therapy called Kisunla (donanemab-azbt) offers hope by slowing the progression of memory loss and cognitive decline.
How Does Kisunla Work?
Kisunla is designed for adults experiencing early symptomatic Alzheimer’s disease, which includes those with mild cognitive impairment (MCI) or mild dementia. The primary focus of Kisunla is on targeting amyloid plaques—abnormal protein deposits in the brain associated with Alzheimer’s.
In clinical trials, Kisunla demonstrated significant success in reducing amyloid plaques. The results were staggering:
- 61% reduction in amyloid plaques at 6 months.
- 80% reduction by 12 months.
- 84% reduction at 18 months.
By targeting these plaques early, Kisunla works to slow the progression of Alzheimer’s and help maintain cognitive functions longer.
Why Kisunla Is Different
While Alzheimer’s treatments can manage symptoms, few target the underlying cause as effectively as Kisunla. In addition to reducing amyloid plaques, Kisunla also helps slow cognitive decline, offering a 35% improvement in cognitive function over 18 months compared to placebo.
For patients in the early stages of Alzheimer’s, this means a more manageable progression of memory and thinking issues, potentially prolonging their ability to maintain independence.
Administration of Kisunla
Kisunla is given through a once-monthly IV infusion, with each session lasting about 30 minutes. This outpatient treatment offers a manageable and convenient solution for patients and their caregivers, without the need for daily medications.
Patients will undergo regular MRI scans to monitor for potential side effects, particularly Amyloid-Related Imaging Abnormalities (ARIA), a side effect that can cause temporary swelling in the brain.
Is Kisunla Right for You?
If you or a loved one are experiencing early symptoms of Alzheimer’s, such as mild cognitive impairment or mild dementia, it’s important to explore all available treatment options. Kisunla offers an innovative approach to slowing the progression of the disease, giving patients more time to manage their condition.
Talk to Your Doctor
As with any medication, it’s crucial to have an open conversation with your healthcare provider about whether Kisunla is the right choice. Your doctor will evaluate your medical history, any medications you’re currently taking, and assess your overall health to determine if Kisunla is a good fit.
For more information on Kisunla and how it could benefit you or a loved one, visit kisunla.lilly.com or speak with your healthcare provider.
Comments
Post a Comment